Abstract Background Pituitary neuroendocrine tumors (PitNETs) are the second most
common intracranial tumor. We lacked a comprehensive understanding of the pathogenesis …

OBJECTIVE Pituitary radiotherapy (RT) is often used as adjuvant treatment in the post‐
operative period for patients with clinically non‐functioning pituitary tumours (NFTs). There is …

Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for
prolactinomas. In most patients, DAs achieve tumor shrinkage and normoprolactinemia at …

Pituitary adenomas are among the most common central nervous system tumors. They
represent a diverse group of neoplasms that may or may not secrete hormones based on …

The cell cycle is regulated by a number of inhibitors, including p27Kip1 (p27), which belongs
to the kip1 family. By binding to the cyclin/cyclin-dependent kinase complexes, it regulates …

Pituitary neuroendocrine tumor (PitNET) is one of the most common intracranial tumors with
variable recurrence rate. Currently, the recurrence prediction is unsatisfying and can be …

Inappropriate secretion of TSH was first described in 1960 in a patient with evidence of
hyperthyroidism and expanded sella on imaging. It was later found that a type of pituitary …

Introduction This publication reviews the function of arginine vasopressin and focuses on the
morphologic and functional correlation between the hormone and its effect on stress, the …

Cushing's disease (CD) is rare in paediatric practice but requires prompt investigation,
diagnosis and therapy to prevent long-term complications. Key presenting features are a …

Human pituitary adenomas are the most common intracranial neoplasms. Approximately 5%
of them are familial adenomas. Patients with familial tumors carry germline mutations in …